Merck: FDA wants more studies of insomnia drug

Drugmaker Merck & Co. says federal regulators have ruled that they won't approve high doses of its experimental insomnia medication because of concerns about their safety.

But Merck says the Food and Drug Administration has indicated it would approve lower doses of the drug, called suvorexant, after Merck provides additional data.

Merck spokesman Steve Cragle says the company is talking with the FDA to determine exactly what studies are needed.

However, the company says that at minimum it will have to do manufacturing studies on a low, 10-milligram dose, which the FDA wants to be the starting dose for most patients. That means Merck will have to repeatedly produce batches at that dose, which it hasn't done before, to show it can produce pills meeting strict specifications.

3.5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

FDA has safety concerns on Merck insomnia drug

May 20, 2013

Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

New sleeping pill poised to hit US markets

May 21, 2013

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Merck says FDA reviewing its ragweed allergy therapy

May 08, 2013

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Recommended for you

New system targets germs in donated blood plasma

18 hours ago

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

India court blocks Bayer generic drug appeal

Dec 13, 2014

An Indian court has rejected German drug giant Bayer's bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drugmaker, a move hailed by activists on Saturday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.